By capturing tumor heterogeneity and its associated molecular pathways, such as immune response and antigen presentation, the model not only enhances biological interpretability but also supports the identification of patients who may benefit from emerging HER2‐targeted therapies, including antibody‐drug conjugates. The gene discussed is ERBB2; the disease is neoplasm.